Key partnership with EmeritusDX getting us 1 step closer to commercializing our MSC test for patients at risk of developing lung cancer. We plan to launch in early 2026! Read more:
https://t.co/nguTmEhe5Y
Exciting news for AccuStem and @EmeritusDX - we are expanding our strategic partnership beyond StemPrintER to operationalize and commercialize the MSC test for clinical use in lung cancer screening in 2026! $ACUT
https://t.co/XZKO3X7b9i
We continue to progress toward commercialization of our MSC lung test as part of lung cancer screening across the US. I am excited to share the news of our partnership expansion with EmeritusDx!
Read more: https://t.co/mi4SUdpWMc
We are pleased to announce the completion of a collaborative agreement that will allow AccuStem to access blood samples from the prospective, multi-center RISP trial. $ACUT
https://t.co/zao9OWvBNw
The AccuStem team continues to partner with top institutions to improve accuracy of lung cancer screening. We look forward to bringing the MSC test to market in 2026!
Read More: https://t.co/Kr4NNxo9fw
As lung cancer screening protocols continue to be established for the millions of patients at risk of lung cancer each year, I am pleased to see the recent data for the MSC lung test published in Lancet Regional Health Europe. Improving outcomes and providing a more definitive diagnosis for those patients with lung nodules is our mission here at AccuStem
Ready the story here: https://t.co/Fu4NK4apnn
Read the journal article here: https://t.co/1Kx8vFNr7H
I am pleased to announce that AccuStem has secured the rights to the novel MSC test that could meaningfully benefit the millions of patients diagnosed with lung nodules each year. We believe the test will provide more definitive diagnoses and peace of mind for patients beyond low dose CT screening alone, with the added benefit of saving costs to the healthcare system.
https://t.co/TxcuV0bU1p
We are excited to announce a partnership with an emerging leader in diagnostics, @EmeritusDX. Together, we will build a stronger foundation of data for #StemPrintER and work to change the way #breastcancer and other types of #cancer are treated. $ACUT https://t.co/qCtyoIMRed
Today we announced that we have extended our partnership with @IEOufficiale to advance our approach to surgical utility of our StemPrintER test. StemPrintER is shown to be highly prognostic for patients at high risk of #breastcancer recurrence. $ACUT
https://t.co/PMX1no5Yg4
A great assay like #StemPrintER needs a strong foundation to ensure the reliability of results and data for patients and their #oncology care teams. Our collaborative partnerships are critical steps that are necessary to support our research and commercialization efforts. $ACUT
My goal is to reach new collectors who may not be familiar with my art. I sell my work at https://t.co/SKHpj5nhYA I’m a self-taught artist from the Lowcountry of South Carolina. Many of my watercolor paintings were made using rain and melted snow. RTs are more than appreciated!